HLA-DQA1*05 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohn's disease patients.

[1]  J. Ludvigsson,et al.  Predictors of drug survival: A cohort study comparing anti‐tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register , 2021, Alimentary pharmacology & therapeutics.

[2]  A. Berghold,et al.  Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study , 2021, Alimentary pharmacology & therapeutics.

[3]  B. Boyle,et al.  Real‐World Infliximab Pharmacokinetic Study Informs an Electronic Health Record‐Embedded Dashboard to Guide Precision Dosing in Children with Crohn’s Disease , 2020, Clinical pharmacology and therapeutics.

[4]  Xiao-Jun Liang,et al.  LncRNA SNHG7 alleviates IL-1β-induced osteoarthritis by inhibiting miR-214-5p-mediated PPARGC1B signaling pathways. , 2020, International immunopharmacology.

[5]  S. Brand,et al.  TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User’s Guide: An Update , 2020, Digestion.

[6]  R. Kim,et al.  HLADQA1*05 genotype predicts anti‐drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease , 2020, Alimentary pharmacology & therapeutics.

[7]  J. Cidlowski,et al.  Inhibition of miR-378a-3p by Inflammation Enhances IL-33 Levels: A Novel Mechanism of Alarmin Modulation in Ulcerative Colitis , 2019, Front. Immunol..

[8]  J. Barrett,et al.  HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. , 2019, Gastroenterology.

[9]  P. Rutgeerts,et al.  Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  W. Sandborn,et al.  Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience , 2018, Inflammatory bowel diseases.

[11]  Hui Shen,et al.  PPARGC1B gene is associated with Kashin-Beck disease in Han Chinese , 2016, Functional & Integrative Genomics.

[12]  S. Bae,et al.  Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis , 2016, Rheumatology International.

[13]  H. Hakonarson,et al.  Molecular Sciences Association between Genetic Polymorphisms and Response to Anti-tnfs in Patients with Inflammatory Bowel Disease , 2022 .

[14]  S. Vermeire,et al.  Review article: pharmacological aspects of anti‐TNF biosimilars in inflammatory bowel diseases , 2015, Alimentary pharmacology & therapeutics.

[15]  J. Yasuda,et al.  Japonica array: improved genotype imputation by designing a population-specific SNP array with 1070 Japanese individuals , 2015, Journal of Human Genetics.

[16]  B. Weiss,et al.  Infliximab-Related Infusion Reactions: Systematic Review , 2015, Journal of Crohn's & colitis.

[17]  Joris M. Mooij,et al.  MAGMA: Generalized Gene-Set Analysis of GWAS Data , 2015, PLoS Comput. Biol..

[18]  Carson C Chow,et al.  Second-generation PLINK: rising to the challenge of larger and richer datasets , 2014, GigaScience.

[19]  A. Moschetta,et al.  PGC-1β promotes enterocyte lifespan and tumorigenesis in the intestine , 2014, Proceedings of the National Academy of Sciences.

[20]  Jianjun Liu,et al.  A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia , 2014, Nature Genetics.

[21]  Jing Wang,et al.  CrossMap: a versatile tool for coordinate conversion between genome assemblies , 2014, Bioinform..

[22]  M. Blennerhassett,et al.  Inflammatory cytokines promote growth of intestinal smooth muscle cells by induced expression of PDGF-Rβ , 2014, Journal of Cellular and Molecular Medicine.

[23]  P. V. Schouwenburg,et al.  Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis , 2013, Nature Reviews Rheumatology.

[24]  D. Mould,et al.  Anti‐TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics‐Based Dosing Paradigms , 2012, Clinical pharmacology and therapeutics.

[25]  Honghui Zhou,et al.  Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. , 2011, Clinical therapeutics.

[26]  S. Ben-Horin,et al.  Review article: loss of response to anti‐TNF treatments in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.

[27]  F. Magro,et al.  Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies , 2010, BioDrugs.

[28]  Michael Boehnke,et al.  LocusZoom: regional visualization of genome-wide association scan results , 2010, Bioinform..

[29]  M. Krzystek-Korpacka,et al.  Platelet-derived growth factor-BB reflects clinical, inflammatory and angiogenic disease activity and oxidative stress in inflammatory bowel disease. , 2009, Clinical biochemistry.

[30]  P. Tak,et al.  Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.

[31]  D. Greaves,et al.  Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. , 2006, Cell metabolism.

[32]  T. Shimosegawa,et al.  FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity , 2013, Immunogenetics.